相似文献
1
Use of amifostine in the treatment of recurrent solid tumours in children.
Hippokratia. 2007 Jan;11(1):25-9.
2
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Cancer. 2001 Aug 15;92(4):914-23. doi: 10.1002/1097-0142(20010815)92:4<914::aid-cncr1401>3.0.co;2-s.
3
The potential of amifostine: from cytoprotectant to therapeutic agent.
Haematologica. 1999 Nov;84(11):1035-42.
4
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Br J Cancer. 2001 Feb 2;84(3):313-20. doi: 10.1054/bjoc.2000.1611.
5
Use of amifostine in the therapy of osteosarcoma in children and adolescents.
J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):188-91. doi: 10.1097/00043426-200203000-00006.
6
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Semin Oncol. 1996 Jun;23(3 Suppl 6):74-7.
7
Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Oncol Nurs Forum. 1998 Apr;25(3):515-23.
8
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Invest New Drugs. 2000 Aug;18(3):281-9. doi: 10.1023/a:1006490226104.
9
Reducing the toxicity of anticancer therapy: new strategies.
Leuk Res. 1998 May;22 Suppl 1:S27-33. doi: 10.1016/s0145-2126(98)00036-8.
10
[Ethyol (amifostine): application trial in pediatric oncology].
Wiad Lek. 1998;51 Suppl 4:215-9.
引用本文的文献
1
Changes in Glutathione Content in Liver Diseases: An Update.
Antioxidants (Basel). 2021 Feb 28;10(3):364. doi: 10.3390/antiox10030364.
2
Flushing Disorders Associated with Gastrointestinal Symptoms: Part 2, Systemic Miscellaneous Conditions.
Clin Med Res. 2018 Jun;16(1-2):29-36. doi: 10.3121/cmr.2017.1379b. Epub 2018 Apr 12.
本文引用的文献
1
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
J Clin Oncol. 2006 Jan 1;24(1):152-9. doi: 10.1200/JCO.2005.02.1717.
2
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Anticancer Drugs. 2003 Apr;14(4):321-6. doi: 10.1097/00001813-200304000-00010.
3
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Clin Cancer Res. 2003 Feb;9(2):703-10.
4
[Effect of amifostine on reducing acute toxicity of megachemotherapy of tumors in children].
Cas Lek Cesk. 2002 May 24;141(10):316-9.
5
Use of amifostine in the therapy of osteosarcoma in children and adolescents.
J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):188-91. doi: 10.1097/00043426-200203000-00006.
6
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Cancer. 2001 Aug 15;92(4):914-23. doi: 10.1002/1097-0142(20010815)92:4<914::aid-cncr1401>3.0.co;2-s.
7
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Med Pediatr Oncol. 2001 Jan;36(1):199-202. doi: 10.1002/1096-911X(20010101)36:1<199::AID-MPO1048>3.0.CO;2-0.
8
Anticancer drug-induced kidney disorders.
Drug Saf. 2001 Jan;24(1):19-38. doi: 10.2165/00002018-200124010-00003.
9
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Br J Cancer. 2001 Jan 5;84(1):19-24. doi: 10.1054/bjoc.2000.1539.
10
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Invest New Drugs. 2000 Aug;18(3):281-9. doi: 10.1023/a:1006490226104.
Zotero 插件